TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Tushar D. Nichakawade(Howard Hughes Medical Institute), Suman Paul(Johns Hopkins University), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Sarah R. DiNapoli(Howard Hughes Medical Institute), Alexander H. Pearlman(Howard Hughes Medical Institute), Surojit Sur(Howard Hughes Medical Institute), Sima Rozati(Johns Hopkins University), Jiaxin Ge(Howard Hughes Medical Institute), Nickolas Papadopoulos(Johns Hopkins University), Maximilian F. Konig(Johns Hopkins University), Nikita Marcou(Howard Hughes Medical Institute), Kenneth W. Kinzler(Johns Hopkins University), Ephraim J. Fuchs(Johns Hopkins University), Brian J. Mog(Howard Hughes Medical Institute), Drew M. Pardoll(Bloomberg (United States)), Sandra B. Gabelli(Johns Hopkins University), Michael S. Hwang(Howard Hughes Medical Institute), Cole Sterling(Sidney Kimmel Comprehensive Cancer Center), Chetan Bettegowda(Johns Hopkins University), Bert Vogelstein(Johns Hopkins University), Nicolas Wyhs(Johns Hopkins University), Shibin Zhou(Johns Hopkins University), Bum Seok Lee(Johns Hopkins University), Stephanie Glavaris(Johns Hopkins University), Lode J. Swinnen(Johns Hopkins University), Evangeline Watson(Howard Hughes Medical Institute)
Cited by 43
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k